Pancreatic Cancer Research

ResearcherOsaka National HospitalActive in the last 2 years

Masanori Tsujie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1265-3397; OpenAlex author ID A5079989633. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
  2. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenoca… Co-author DOI 10.1038/s41598-025-23185-7↗
  3. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  4. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  5. [A Case of Resection of Sigmoid Colon Metastasis from Pancreatic Cancer]. Co-author PMID 36733076↗
  6. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
  7. A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases. Co-author DOI 10.1016/j.ijscr.2020.06.044↗
  8. [Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable Pancreatic Cancer]. Co-author PMID 31501367↗
  9. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. Co-author DOI 10.1016/j.hbpd.2018.01.004↗
  10. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.006↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tadafumi Asaoka · 7 shared papers, 2016–2026 · strength 1.01
  2. Masahiro Tanemura · 5 shared papers, 2021–2026 · strength 0.87
  3. Yuichiro Doki · 5 shared papers, 2021–2026 · strength 0.87
  4. Hirofumi Akita · 5 shared papers, 2021–2026 · strength 0.87
  5. Yoshifumi Iwagami · 4 shared papers, 2024–2026 · strength 0.77
  6. Hidetoshi Eguchi · 4 shared papers, 2021–2026 · strength 0.67
  7. Osakuni Morimoto · 4 shared papers, 2021–2025 · strength 0.65
  8. Daisaku Yamada · 4 shared papers, 2021–2025 · strength 0.65
  9. Yutaka Takeda · 4 shared papers, 2021–2025 · strength 0.65
  10. Hidenori Takahashi · 3 shared papers, 2021–2024 · strength 0.45
  11. Chikato Koga · 2 shared papers, 2022–2026 · strength 0.36
  12. Masahiro Murakami · 2 shared papers, 2021–2026 · strength 0.32
  13. Yoshito Tomimaru · 1 shared paper, 2026 · strength 0.22
  14. Hiroshi Wada · 1 shared paper, 2026 · strength 0.22
  15. Yoshiteru Katsura · 1 shared paper, 2026 · strength 0.22
  16. Hidetoshi Eguchi · 1 shared paper, 2025 · strength 0.20
  17. Masatoshi Inoue · 2 shared papers, 2019–2020 · strength 0.17
  18. Shoji Nakamori · 2 shared papers, 2016–2018 · strength 0.14
  19. Atsushi Miyamoto · 2 shared papers, 2016–2018 · strength 0.14
  20. Mitsugu Sekimoto · 2 shared papers, 2016–2018 · strength 0.14
  21. Yusuke Akamaru · 1 shared paper, 2022 · strength 0.14
  22. Rintaro Matsumura · 1 shared paper, 2022 · strength 0.14
  23. Soichiro Mori · 1 shared paper, 2022 · strength 0.14
  24. Motohiro Hirao · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.